122 related articles for article (PubMed ID: 22273319)
21. Decrease of CD117 expression as possible prognostic marker for recurrence in the resected specimen after imatinib treatment in patients with initially unresectable gastrointestinal stromal tumors: a clinicopathological analysis.
Mearadji A; den Bakker MA; van Geel AN; Eggermont AM; Sleijfer S; Verweij J; de Wilt JH; Verhoef C
Anticancer Drugs; 2008 Jul; 19(6):607-12. PubMed ID: 18525320
[TBL] [Abstract][Full Text] [Related]
22. Adjuvant imatinib treatment improves recurrence-free survival in patients with high-risk gastrointestinal stromal tumours (GIST).
Nilsson B; Sjölund K; Kindblom LG; Meis-Kindblom JM; Bümming P; Nilsson O; Andersson J; Ahlman H
Br J Cancer; 2007 Jun; 96(11):1656-8. PubMed ID: 17533389
[TBL] [Abstract][Full Text] [Related]
23. Risk criteria and prognostic factors for predicting recurrences after resection of primary gastrointestinal stromal tumor.
Rutkowski P; Nowecki ZI; Michej W; Debiec-Rychter M; Woźniak A; Limon J; Siedlecki J; Grzesiakowska U; Kakol M; Osuch C; Polkowski M; Głuszek S; Zurawski Z; Ruka W
Ann Surg Oncol; 2007 Jul; 14(7):2018-27. PubMed ID: 17473953
[TBL] [Abstract][Full Text] [Related]
24. [An update of the surgical indications for gastrointestinal stromal tumors].
Bonvalot S
J Chir (Paris); 2008; 145 Suppl 3():6S8-11. PubMed ID: 19060842
[TBL] [Abstract][Full Text] [Related]
25. Adjuvant imatinib therapy for gastrointestinal stromal tumors.
Pisters PW; Colombo C
J Surg Oncol; 2011 Dec; 104(8):896-900. PubMed ID: 22069174
[TBL] [Abstract][Full Text] [Related]
26. Gastrointestinal stromal tumors and the evolution of targeted therapy.
Sanborn RE; Blanke CD
Clin Adv Hematol Oncol; 2005 Aug; 3(8):647-57. PubMed ID: 16167051
[TBL] [Abstract][Full Text] [Related]
27. Population-based study of the diagnosis and treatment of gastrointestinal stromal tumours.
Bümming P; Ahlman H; Andersson J; Meis-Kindblom JM; Kindblom LG; Nilsson B
Br J Surg; 2006 Jul; 93(7):836-43. PubMed ID: 16705644
[TBL] [Abstract][Full Text] [Related]
28. Gastrointestinal stromal tumours. Is aggressive surgical treatment reasonable in locally advanced cases?
Ascenzi P; Orienti L; Okoro U; Raspanti A; Ucchino G
Chir Ital; 2009; 61(5-6):559-64. PubMed ID: 20380258
[TBL] [Abstract][Full Text] [Related]
29. The effect of neoadjuvant Imatinib therapy on outcome and survival after rectal gastrointestinal stromal tumour.
Machlenkin S; Pinsk I; Tulchinsky H; Ziv Y; Sayfan J; Duek D; Rabau M; Walfisch S
Colorectal Dis; 2011 Oct; 13(10):1110-5. PubMed ID: 21040362
[TBL] [Abstract][Full Text] [Related]
30. Surgical management and clinical outcome of gastrointestinal stromal tumor of the colon and rectum.
Chen CW; Wu CC; Hsiao CW; Fang FC; Lee TY; Che FC; Tsai WC; Jao SW
Z Gastroenterol; 2008 Aug; 46(8):760-5. PubMed ID: 18759198
[TBL] [Abstract][Full Text] [Related]
31. Serum midkine correlates with tumor progression and imatinib response in gastrointestinal stromal tumors.
Rawnaq T; Kunkel M; Bachmann K; Simon R; Zander H; Brandl S; Sauter G; Izbicki JR; Kaifi JT
Ann Surg Oncol; 2011 Feb; 18(2):559-65. PubMed ID: 20589434
[TBL] [Abstract][Full Text] [Related]
32. Adjuvant and down-staging treatment with imatinib in gastrointestinal stromal tumors.
Nilsson B; Andersson A; Ahlman H
J Surg Oncol; 2008 Sep; 98(3):145-6. PubMed ID: 18452216
[No Abstract] [Full Text] [Related]
33. [Surgical treatment of an advanced GIST the age of imatinib].
Fernández JA; Parrilla P
Cir Esp; 2009 Jul; 86(1):3-12. PubMed ID: 19539273
[TBL] [Abstract][Full Text] [Related]
34. Congestive heart failure in a 77-year-old woman receiving adjuvant treatment with imatinib for a large gastric gastrointestinal stromal tumour.
Pulido EG; Riquelme A; Ballesteros J; Vaz MÁ
Anticancer Drugs; 2012 Jun; 23 Suppl():S15-7. PubMed ID: 22739666
[TBL] [Abstract][Full Text] [Related]
35. Prognostic stratification of high-risk gastrointestinal stromal tumors in the era of targeted therapy.
Keun Park C; Lee EJ; Kim M; Lim HY; Choi DI; Noh JH; Sohn TS; Kim S; Kim MJ; Lee HK; Kim KM
Ann Surg; 2008 Jun; 247(6):1011-8. PubMed ID: 18520229
[TBL] [Abstract][Full Text] [Related]
36. Tumor mitotic rate, size, and location independently predict recurrence after resection of primary gastrointestinal stromal tumor (GIST).
Dematteo RP; Gold JS; Saran L; Gönen M; Liau KH; Maki RG; Singer S; Besmer P; Brennan MF; Antonescu CR
Cancer; 2008 Feb; 112(3):608-15. PubMed ID: 18076015
[TBL] [Abstract][Full Text] [Related]
37. [New surgical approaches to localized and advanced gastrointestinal stromal tumors (GIST)].
Bonvalot S; Honoré C
Bull Acad Natl Med; 2012; 196(4-5):855-60; discussion 860. PubMed ID: 23550448
[TBL] [Abstract][Full Text] [Related]
38. Imatinib mesylate treatment for advanced gastrointestinal stromal tumor: a pilot study focusing on patients experiencing sole liver metastasis after a prior radical resection.
Zhu J; Wang Y; Hou M; Li HY; Zhang J
Oncology; 2007; 73(5-6):324-7. PubMed ID: 18497504
[TBL] [Abstract][Full Text] [Related]
39. A prospective, multicenter, phase 2 study of imatinib mesylate in korean patients with metastatic or unresectable gastrointestinal stromal tumor.
Ryu MH; Kang WK; Bang YJ; Lee KH; Shin DB; Ryoo BY; Roh JK; Kang JH; Lee H; Kim TW; Chang HM; Park JO; Park YS; Kim TY; Kim MK; Lee WK; Kang HJ; Kang YK
Oncology; 2009; 76(5):326-32. PubMed ID: 19307738
[TBL] [Abstract][Full Text] [Related]
40. [Long-term survival after surgery and adjuvant imatinib in a patient with rectal GIST, local recurrence, liver metastases and mediastinal pleural metastasis].
Tsutsui M; Yoshino S; Sakamoto K; Oka M
Gan To Kagaku Ryoho; 2009 Nov; 36(12):2351-3. PubMed ID: 20037419
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]